✦ LIBER ✦

Successful retreatment with infliximab in patients with prior severe infusion reactions

✍ Scribed by Imad Uthman; Zahi Touma; Jinane El-Sayyad; Fares Zaitoun

Book ID: 106264267
Publisher: Springer
Year: 2005
Tongue: English
Weight: 58 KB
Volume: 25
Category: Article
ISSN: 0770-3198
DOI: 10.1007/s10067-005-0029-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful induction of tolerance to inf

Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions

✍ C. DUBURQUE; J. LELONG; R. IACOB; M. SEDDIK; P. DESREUMAUX; C. FOURNIER; B. WALL 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 604 KB

Severe infusion reactions to infliximab:

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

✍ C. Steenholdt; M. Svenson; K. Bendtzen; O. Ø. Thomsen; J. Brynskov; M. A. Ainswo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB

Successful retreatment with alitretinoin

Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema

✍ R. Bissonnette; M. Worm; B. Gerlach; L. Guenther; F. Cambazard; T. Ruzicka; J. M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB

Elevated serum IgE prior to acute severe

Elevated serum IgE prior to acute severe infusion reaction during infliximab maintenance therapy in a crohn's disease patient

✍ Shingo Kato; Taisuke Kobayashi; Kazuhito Kani; Hidehiko Takabayashi; Ryuichi Yam 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

The impact of infliximab infusion reacti

The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn’s disease

✍ A. C. MOSS; N. FERNANDEZ-BECKER; K. JO KIM; D. CURY; A. S. CHEIFETZ 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Are accelerated infliximab infusions saf

Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?

✍ Shivaram Bhat; Divyesh Sharma; Pauline Doherty; Tony C.K. Tham; Grant R. Caddy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Background: Infliximab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). The manufacturerrecommended administration is over 2 hours followed by 2 hours of patient observation. The data relating to adverse outcomes in patients receiving accelerated infusions for IBD